STOCKS TELEGRAPH

Category: Mid Day Movers

  • Pre-Market Boost For Celestica (CLS) As Investors React To Earnings Report

    Pre-Market Boost For Celestica (CLS) As Investors React To Earnings Report

    As of the most recent check, Celestica Inc. (NYSE: CLS) share price jumped 13.28% to $113.84 during the pre-market session today. The surge followed the release of the company’s fourth-quarter earnings report, which highlighted exceptional financial success and great fiscal year 2024 results.

    Better Performance and Improved Outlook

    Celestica’s fourth-quarter revenues of $2.55 billion represented a 19% increase over the prior year. Additionally, the company’s quarterly non-GAAP adjusted EPS of $1.11 was its highest ever. Due to its outstanding success, Celestica has increased its financial forecasts for 2025.

    The company’s full-year revenue projection has been raised from $10.4 billion to $10.7 billion. Additionally, it has increased its non-GAAP adjusted EPS expectation from $4.42 to $4.75. The increased prediction is primarily driven by growing demand within its Connectivity & Cloud Solutions (CCS) sector, which is continuing showing strong momentum.

    Supporting Indicators

    Market indicators further support Celestica’s positive trajectory. On the ST screener, CLS holds a score of 54, with a profit margin exceeding 4%. Investors seeking industry comparisons can explore a compiled list of peer stocks in the Hardware, Equipment, and Parts sector with stronger ST scores and profit margins.

    Expanding AI and Data Center Initiatives

    Celestica remains optimistic about sustained growth in the data center hardware market. Recent customer forecasts and new artificial intelligence (AI) program awards over the past 90 days reinforce the company’s belief that demand will extend into 2026.

    Notably, Celestica secured a 1.6 Terabyte switching program contract with a second Hyperscaler client. Under its Hardware Platform Solutions (HPS) initiative, the company will design and manufacture an AI-optimized networking rack featuring advanced system-level liquid cooling technology, with production slated for 2026.

    Celestica Entered A New Collaboration

    Additionally, Celestica announced a new HPS program collaboration with a leading Digital Native Company. The initiative involves delivering a fully integrated, AI-optimized rack system, leveraging proprietary R&D investments in AI/ML servers, high-capacity switches, and advanced cooling technologies. Production for this program is expected to commence in late 2026.

  • InflaRx (IFRX) Stock Sees After-Market Gains

    InflaRx (IFRX) Stock Sees After-Market Gains

    After-hours trading on Wednesday saw InflaRx N.V. (NASDAQ: IFRX) shares rise 11.61%, finishing at $2.50. This spike, which comes before the firm takes part in a major industry event, indicates that investors are becoming more optimistic about the company’s prospects for the future. Moreover, IFRX has an ST score of 40 on our screener in the biotechnology industry. Visit our screener link if you’re interested in biotechnology stocks with higher scores.

    InflaRx to Showcase Innovations at Guggenheim Biotech Conference

    InflaRx will be attending the esteemed Guggenheim SMID Cap Biotech Conference, which will take place in New York, NY, on February 5–6, 2025. The business, which is renowned for its groundbreaking work in anti-inflammatory treatments, especially for its improvements in complement system targeting, is anticipated to showcase its most recent studies and clinical breakthroughs. The event will be eagerly watched by investors and industry professionals as it offers InflaRx a chance to strengthen its standing in the biotech industry.

    EU Grants Exceptional Marketing Authorization for GOHIBIC

    InflaRx has been granted permission by the European Commission (EC) to market GOHIBIC or vilobelimab under special conditions, which is a major regulatory milestone. Adult patients with COVID-induced acute respiratory distress syndrome, or ARDS, are treated with systemic corticosteroids and invasive mechanical ventilation, or IMV, with or without extracorporeal membrane oxygenation, or ECMO.

    GOHIBIC, the first and only approved drug for COVID-induced acute respiratory distress syndrome in the EU, exemplifies InflaRx’s commitment to addressing critical care units’ pressing unmet medical needs. The authorization extends to Iceland, Liechtenstein, Norway, and all 27 EU countries. InflaRx is looking at local business partnerships and distribution, but the company does not anticipate that these efforts will significantly lower its capital burn rate.

    Emergency Use Permission in the United States

    If administered within 48 hours after the initiation of IMV or ECMO, the GOHIBIC Emergency Use Authorization (EUA) has been approved by the US Food and Drug Administration (FDA) to treat hospitalized patients with COVID-19. The EUA remains in place for the duration of the COVID-19 public health emergency, providing temporary access to this essential treatment option for healthcare providers.

  • Signing Day (SGN) Shares Skyrocket Following Strategic Equity Acquisition

    Signing Day (SGN) Shares Skyrocket Following Strategic Equity Acquisition

    Signing Day Sports, Inc. (NYSE: SGN) experienced a significant surge in its stock value following the announcement of an equity purchase agreement, driving its shares 124.74% higher to $4.36. According to our ST screener ratings in the Software Application industry, SGN is considered undervalued, drawing investor interest. Stakeholders seeking deeper insights into peer stocks with higher scores are encouraged to review the ST screener link for further analysis.

    Acquisition of Swifty Global to Strengthen Growth Prospects

    Signing Day Sports has entered into a Stock Purchase Agreement (SPA) to acquire 99.13% of the issued and outstanding capital stock of Dear Cashmere Group Holding Company (OTC: DRCR), operating under the brand name Swifty Global.

    Swifty Global specializes in online sports and casino technology, boasting a strong track record of revenue growth and profitability. This acquisition is expected to significantly enhance the growth trajectory of Signing Day Sports by leveraging Swifty Global’s established market presence and innovative solutions.

    The Financial Results and Growth Plan of Swifty Global

    With nearly $128 million in revenue and a net profit of over $2.44 million for the fiscal year that ended on December 31, 2023, Swifty Global announced outstanding financial performance. It was achieved despite significant expenditures of around $3.1 million for software development and licensing efforts.

    Swifty Global intends to fill current market gaps where real-time betting data is still scarce, especially in sports like boxing, by launching data feed services specifically designed for the online sports gambling sector soon.

    Strategic Synergy and Future Outlook

    The SPA agreement underscores a shared vision between Signing Day Sports and Swifty Global to drive innovation and market expansion. Signing Day Sports aims to leverage Swifty Global’s SaaS technology to enhance operational efficiencies, reduce costs by over 50%, and accelerate product development.

    This collaboration is expected to boost user acquisition, retention, and revenue streams while facilitating expansion into emerging markets across Europe, Africa, and the Middle East. Upon completion of the SPA, Swifty Global will operate as a subsidiary of Signing Day Sports, with full integration of financial results into the parent company’s operations.

    Likewise, Signing Day Sports’ pre-acquisition business will function as a subsidiary under the corporate structure. This strategic move positions Signing Day Sports as a formidable player in the global sports technology industry, committed to innovation and sustained growth.

  • DJT Shares Climb As Trump Media Unveils Growth Plans

    DJT Shares Climb As Trump Media Unveils Growth Plans

    Shares of Trump Media & Technology Group Corp. (NASDAQ: DJT) experienced a notable increase following the company’s announcement of a strategic expansion into financial services and financial technology. As of the latest market check, DJT stock had risen by 6.36%, reaching a trading price of $31.95.

    Introduction of Truth.Fi and Strategic Investment Moves

    The creation of a new financial services and FinTech brand, Truth.Fi, has been approved by Trump Media’s board of directors. Trump Media is the parent business of the social media network Truth Social and the video streaming service Truth+. By using this strategy, the company hopes to achieve its main objective of diversifying its operations and strengthening its financial position.

    To optimize its $700 million cash and cash-equivalent reserves, the board has authorized the transfer of up to $250 million to be held with Charles Schwab. The investing approach for these funds will include traditional financial instruments, tailored exchange-traded funds (ETFs), separately managed accounts (SMAs), and cryptocurrency-related assets such as Bitcoin.

    Forming Strategic Partnerships to Advance Development

    Trump Media has partnered with Charles Schwab to develop SMAs and oversee investment strategies for Truth.Fi. Additionally, an affiliate of Yorkville Advisors will serve as the Registered Investment Adviser for various investment products. These financial vehicles will primarily focus on American growth sectors, manufacturing, and energy industries while supporting what the company terms the “Patriot Economy.”

    A New Phase in Trump Media’s Expansion

    The introduction of Truth.Fi marks a significant evolution of Trump Media’s business model, building upon its existing free-speech social media platform and ultra-fast streaming service. With this expansion into investment products and decentralized finance, the company aims to create an ecosystem that enables American investors to safeguard their assets from perceived risks associated with mainstream financial institutions.

    Performance & Growth Impact

    With DJT maintaining an ST score of 34 and a three-month average trading volume exceeding 30 million shares, market analysts will closely watch the company’s financial sector expansion and its impact on the Internet Content & Information industry. Visit the ST screener link to learn more about the peer stock that scored higher.

  • Paragon 28 (FNA) Gains Market Momentum After Acquisition Deal Unveiled

    Paragon 28 (FNA) Gains Market Momentum After Acquisition Deal Unveiled

    Reports of an acquisition agreement with Zimmer Biomet, a world leader in medical technology, caused shares of Paragon 28, Inc. (NYSE: FNA) to soar. The stock of FNA was up 8.41% at $13.01 as of the most recent market summary. The stock has demonstrated a Bullish performance in the Medical Devices industry, with a score of 44 on our ST screener. Visit screener link for a more thorough review of comparable peer stocks.

    Paragon 28 Entered Acquisition Deal

    A definitive agreement between Paragon 28 and Zimmer Biomet stipulates that all of the company’s remaining shares will be bought. With an enterprise value of $1.2 billion and an equity value of about $1.1 billion, the cash purchase price is fixed at $13.00 per share.

    FNA shareholders will also get a non-tradeable contingent value right (CVR), which provides the opportunity to receive up to $1.00 in cash per share in the event that specific revenue milestones are met. The payout is dependent on Zimmer Biomet’s fiscal year 2026 net revenues surpassing $346 million to $361 million.

    Strategic Expansion in the Foot and Ankle Market

    Offering a wide spectrum of fracture and trauma, deformity treatment, and joint replacement devices, Paragon 28 specializes in foot and ankle surgery solutions. The purchase will boost Zimmer Biomet’s position in the rapidly expanding musculoskeletal care industry and diversify its company beyond core orthopedics. Cross-selling opportunities in the quickly growing Ambulatory Surgery Center (ASC) market are also presented by the purchase.

    By utilizing Paragon 28’s creative product pipeline and skilled sales team to meet the intricate needs of foot and ankle therapies, the combination complements Zimmer Biomet’s growth plan. Given Zimmer Biomet’s global footprint, the purchase is anticipated to propel growth in the United States and abroad, strengthening the business’s position in the $5 billion foot and ankle market.

    A New Era for Paragon 28

    Paragon 28 wil remain improving patient outcomes and creating foot and ankle care. The company views the acquisition as a revolutionary step that will allow it to use Zimmer Biomet’s extensive resources and infrastructure while furthering its mission.

  • T-Mobile (TMUS) Surges In Pre-Market As Strong Earnings Boost Confidence

    T-Mobile (TMUS) Surges In Pre-Market As Strong Earnings Boost Confidence

    T-Mobile US, Inc. (NASDAQ: TMUS) saw a noteworthy pre-market rally, rising 7.28% to $237.25. The surge in TMUS stock after revealing its great earnings growth for the fourth quarter and the whole year 2024 is a demonstration of investor confidence in TMUS’ ability to maintain its growth despite escalating competition.

    Client Acquisition and Market Development

    T-Mobile continued to dominate the industry with record customer additions across multiple segments. High-speed internet subscriptions increased significantly, while postpaid and prepaid subscriber growth remained robust. It’s Q4 postpaid phone churn was its lowest ever, highlighting strong customer loyalty and retention. By the end of 2024, T-Mobile had added a record 129.5 million new users, solidifying its stronghold in the market.

    Good Financial Standing and Shareholder Returns

    T-Mobile’s consistent increase in overall service revenues was primarily driven by strong gains in postpaid service revenue. The notable year-over-year increases in net income and diluted earnings per share (EPS) indicated strong financial performance. The firm successfully returned $14.4 billion to shareholders as part of its long-term growth strategy, demonstrating its commitment to giving investors value. T-Mobile is well-positioned for future growth and innovation because to its strong financial position.

    Growth and Innovation in the Future

    The leadership of T-Mobile attributed its success to smart investments in network infrastructure and a customer-centric strategy. The business is still committed to growing its 5G network and providing innovative solutions to improve client experiences. T-Mobile is well-positioned to use its dominant market position and technical innovations to propel future development as competition heats up.

    Strong Buy Rating and Top Performers

    TMUS has a Strong Buy rating on our ST screener, with IRDM and KT also ranking among the top performers with even better ST scores. We have compiled a list of similarly rated stocks in the telecommunications industry with even higher ST scores. Investors can visit our ST screener list to gain more detailed insights into top-performing stocks in the sector.

  • Pre-Hour Stock Surge: Planet Labs (PL) Sees Upward Trend

    Pre-Hour Stock Surge: Planet Labs (PL) Sees Upward Trend

    Shares of Planet Labs PBC (NYSE: PL) have demonstrated a notable uptick, climbing 6.96% in premarket trading to reach $5.84. This surge follows a previous session increase of 13.01%, closing at $6.17. The company, a leading provider of Earth observation data, currently holds a market capitalization of $1.63 billion and an ST score of 57 within the Aerospace & Defense sector.

    In comparison, peer companies such as DCO and DRS have achieved higher scores of 64 and 62, respectively. For additional comparable stocks with a market value of over $300 million and even higher ST scores, investors may click on our ST screener link.

    Working along with the European Space Agency

    Planet Labs announced the signing of a multi-year deal with the European Space Agency (ESA), reinforcing its position as a key contributor to the Copernicus Contributing Missions. Under this contract, Planet Labs will integrate its commercial satellite data with ESA’s Sentinel satellite system to enhance the data offerings for Copernicus services.

    Through this collaboration, Planet Labs will provide near-daily PlanetScope satellite imagery along with high-resolution SkySat imagery. These datasets will complement ESA’s existing portfolio, offering geospatial analysts a broader and more diversified range of resources to meet various analytical needs. ESA’s dedication to integrating commercial satellite data from up-and-coming New Space firms is demonstrated by this arrangement.

    Enhancing an Established Partnership

    Over the years, Planet Labs and ESA have remained close partners. The company’s PlanetScope and SkySat satellite constellations will continue to serve the Copernicus Program as a Contributing Mission with this new contract. Europe continues to lead the world in Earth observation innovation, and Planet Labs sees this sustained investment in commercial space technology as evidence of that.

    Increasing Commercial and Research Uses

    Prior to this agreement, Planet Labs collaborated with ESA for over a decade, contributing to both the Copernicus initiative and the ESA Third Party Mission program. This partnership has enabled researchers and businesses within ESA and European Commission Member States to leverage Planet Labs’ satellite imagery for a variety of applications, including land use monitoring and climate change research. Through continued cooperation, Planet Labs and ESA aim to drive advancements in scientific research and commercial space services.

  • Silexion (SLXN) Stock Rallies In Pre-Hour Market Amid Promising Study Results

    Silexion (SLXN) Stock Rallies In Pre-Hour Market Amid Promising Study Results

    Shares of Silexion Therapeutics Corp (NASDAQ: SLXN) experienced a significant surge in premarket trading, rising 52.59% to $2.06 following the release of promising preclinical study results. Over the past week, SLXN has recorded a gain exceeding 70% on ST screener, placing it among the top-performing biotechnology stocks.

    While SLXN has shown impressive momentum, other biotech firms, including DOMH and ELTX, have demonstrated even higher price performance. To get more insight about similar stock, visit our screener link.

    Significant Progress in the Treatment of Pancreatic Cancer

    Silexion Therapeutics revealed promising preclinical results for SIL-204, a next-generation small interfering RNA (siRNA) therapeutic candidate. The study highlights the efficacy of systemic administration as a viable delivery mechanism, showcasing a marked reduction in tumor growth within orthotopic pancreatic cancer models—an approach designed to closely replicate human disease progression.

    These findings underscore the potential of SIL-204 in addressing one of the most aggressive forms of cancer, particularly through its targeted inhibition of KRAS mutations, which play a crucial role in tumor development.

    Preclinical Success and Future Development Plans

    The latest data reveal that SIL-204, when delivered in an extended-release formulation, led to approximately 50% tumor growth reduction over 30 days, with half of the treated tumors exhibiting complete necrosis in xenografted human pancreatic tumors containing the G12D mutation.

    Furthermore, in mice with metastatic pancreatic cancer models, subcutaneous administration of SIL-204 effectively inhibited tumor progression; additionally, a single systemic dose maintained effective drug levels in plasma and tissues for more than 56 days, demonstrating sustained therapeutic activity against KRAS mutations, including G12D, G12V, G12R, Q61H, and G13D.

    Broadening the Scope of Cancer Treatment

    With these encouraging results, Silexion Therapeutics is now focused on utilizing them to improve and broaden its approach to treating KRAS-driven cancers. The company expects to release more information about its comprehensive development plan soon.

    SIL-204 has demonstrated its promise as a game-changing treatment for pancreatic and other advanced malignancies by successfully targeting important oncogenic pathways. In this difficult treatment environment, the business is certain that it can prevent metastatic progression and enhance patient outcomes as research advances.

  • Siyata (SYTA) Stock Gains Momentum After Securing Key Order

    Siyata (SYTA) Stock Gains Momentum After Securing Key Order

    Shares of Siyata Mobile Inc. (NASDAQ: SYTA) experienced a sharp rise of 14.39%, reaching $5.62, following the announcement of a significant new order. SYTA disclosed securing a deal to supply several thousand SD7 handsets and related accessories to a prominent transit authority in the western United States.

    The New Partnership

    The deal marks a key milestone in Siyata Mobile’s ongoing expansion within the transit and public works sectors across the country. The transit authority, which handles tens of millions of passengers every year, is updating its communication systems by using Siyata’s Push-to-Talk over Cellular (PoC) technologies to replace antiquated radio-based infrastructure.

    Another Joint Venture

    Siyata Mobile has strengthened its market position by working with JVCKenwood USA in addition to this order. Through this partnership, its SD7 handsets will be marketed under the Kenwood brand, targeting JVCKenwood’s channel partners and critical business customers.

    The Safety & Security Sector of JVCKenwood USA introduced these PoC handsets as part of their offerings for enterprise and public service workers, enabling instant communication via a nationwide cellular network. JVCKenwood’s extensive distribution network of thousands of dealers across North America is set to further amplify the reach of Siyata Mobile’s devices.

    Advancing Communication Technology

    JVCKenwood has a long history of providing its clients with state-of-the-art communication solutions. It is anticipated that the addition of Siyata’s PoC technology to JVCKenwood’s LMR portfolio would enhance operational safety and communication dependability in emergency scenarios. The partnership signifies a shared commitment to providing innovative communication tools for essential sectors.

    Stock Performance and Industry Insights

    As of now, SYTA stock is listed as “Undervalued” on our ST screeners, with other companies like VISL and ANVW also showing promising valuations. For investors, the Communication Equipment industry presents diverse opportunities for growth. A detailed list of undervalued stocks in the industry is available through our screener for better investment opportunities.

  • Equity News Drives NRx Pharmaceuticals (NRXP) Stock Higher

    Equity News Drives NRx Pharmaceuticals (NRXP) Stock Higher

    Shares of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) have experienced a remarkable surge of 21.05%, reaching $3.45 as of the latest market check, following the announcement of an equity move. This notable increase comes after the company revealed its plan to raise capital through a registered direct offering of common stock.

    Senior Secured Convertible Notes and Equity Offering

    The pharmaceutical business has signed a legally binding contract to sell its common shares in a registered direct offering, with an anticipated gross profit of about $3.5 million. NRx Pharmaceuticals intends to issue senior secured convertible promissory notes in addition to the stock offering, which should generate an extra $5.4 million from the same institutional investors. The securities purchase agreement dated August 12, 2024, is in compliance with this issuance.

    Funding to Support Key Initiatives

    NRx intends to use the proceeds from both the stock offering and the notes issuance to support several critical initiatives, including the filing of New Drug Applications (NDAs) for its lead products, NRX-100 and NRX-101. These drugs are designed to address suicidal depression and potentially PTSD, both conditions that have long required new treatment options.

    Additionally, the funds will support the launch of HOPE Therapeutics, an initiative focused on delivering cutting-edge psychiatric care, and potentially fund the acquisition of additional pipeline assets.

    Path to Profitability

    The combined financing is expected to sustain the company’s operations through 2026, bolstered by anticipated product sales and non-dilutive funding. NRx Pharmaceuticals is confident that this financial strategy will enable the company to reach profitability. Furthermore, the funding could help close non-dilutive financing aimed at acquiring profitable interventional psychiatry clinics to expand HOPE Therapeutics’ reach.

    Impressive Market Performance

    NRXP stock has experienced a remarkable 90% rise over the past month, drawing attention from investors. Those seeking detailed insights on high-performing stocks in the Biotechnology industry are encouraged to explore our ST screener list for informed decision-making.